VYNE Stock Analysis: Buy, Sell, or Hold?
VYNE - VYNE Therapeutics Inc. Common Stock
$0.57
-0.02 (-2.91%)
▼
5d:
-6.59%
30d:
-4.4%
90d:
-2.38%
HOLD
LOW Confidence
Analysis Updated: Mar 30, 2026 12:00 AM ET
Earnings: May 14, 2026
Get Alerted When VYNE Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: VYNE shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: VYNE shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: VYNE is currently trading at $0.57, which is considered oversold relative to its 30-day fair value range of $0.58 to $0.61.
Technical Outlook: Technically, VYNE is in a strong uptrend. The price is currently testing key support at $0.57. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $2.00 (+238.3%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, VYNE is in a strong uptrend. The price is currently testing key support at $0.57. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $2.00 (+238.3%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$0.58 -
$0.61
Company Quality Score
60/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
82.6%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 238.3% below Wall St target ($2.00)
- CAUTION: Recommendation downgraded due to -6.6% 5-day decline
Fair Price Analysis
30-Day Fair Range
$0.58 -
$0.61
Current vs Fair Value
OVERSOLD
Support & Resistance Levels
Support Level
$0.57
Resistance Level
$0.63
Current Trend
Strong Uptrend
Technical data as of
Mar 30, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.36
Wall Street Target
$2.00
(+238.3%)
Revenue Growth (YoY)
54.8%
Share & Embed Analysis
Last updated: March 30, 2026 3:22 PM ET
Data refreshes hourly during market hours. Next update: 4:22 PM
Data refreshes hourly during market hours. Next update: 4:22 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is VYNE showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
33 analysts |
$449 | 56 HOLD |
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$94 | 59 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$33 | 45 HOLD |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
20 analysts |
$119 | 54 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$101 | 60 HOLD |
